Collegium Pharmaceutical (COLL) Non-Current Assets (2014 - 2026)

Collegium Pharmaceutical has reported Non-Current Assets for 13 years, with the latest figure at $1.5 billion in Q2 2026.

• On a quarterly basis, Non-Current Assets rose 46.42% year-over-year to $1.5 billion in Q2 2026; TTM through Jun 2026 was $4.4 billion, a 2.81% decrease from a year earlier, with the FY2025 full-year figure at $965.4 million, down 18.28% from the prior year.
• Non-Current Assets was $1.5 billion for Q2 2026 at Collegium Pharmaceutical, up from $906.3 million in the prior quarter.
• The five-year high for Non-Current Assets was $1.5 billion in Q2 2026, with the low at $543.2 million in Q2 2024.
• Average Non-Current Assets over 5 years is $885.4 million, with a median of $859.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 152.32% in 2022, then declined 19.72% in 2024.
• Over 5 years, Non-Current Assets stood at $754.1 million in 2022, then decreased by 19.68% to $605.7 million in 2023, then soared by 95.03% to $1.2 billion in 2024, then slipped by 18.28% to $965.4 million in 2025, then soared by 58.25% to $1.5 billion in 2026.
• The last three Non-Current Assets figures came in at $1.5 billion (Q2 2026), $906.3 million (Q1 2026), and $965.4 million (Q4 2025), per Business Quant data.